Great commentary, and good idea looking at another producer to get a handle on Mn con pricing. I thought the Mn pricing might be the “catch” in the study which caused the market to hold back on the stock, so makes sense the current actual price is much lower than their study value. Discount rate of 8% is typical at the moment, but would agree something like 10% probably more relevant for an early stage study in thie current cost environment.
Ann: Updated Oakover DMS Concentrate Scoping Study Delivers, page-9
Add FRB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.029(31.9%) |
Mkt cap ! $17.08M | |||
| Open | High | Low | Value | Volume |
| 9.1¢ | 12.5¢ | 9.1¢ | $23.22K | 204.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25641 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 20000 | 1 |
View Market Depth
| Last trade - 15.57pm 19/11/2024 (20 minute delay) ? |
| FRB (ASX) Chart |